City of Hope Researchers Highlight Advances in Cancer Therapies at ASCO 2026
City of Hope researchers are presenting significant advancements in cancer treatment at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentations include findings from 49 abstracts covering solid tumors and blood cancers. Key highlights include the phase 3 SUNMO trial, which shows that a combination of mosunetuzumab and polatuzumab vedotin improves outcomes for patients with relapsed or refractory large B-cell lymphoma. The study demonstrated a 70.3% objective response rate compared to 40.0% for standard therapy. Additionally, research on the gut microbiome's influence on immunotherapy outcomes in kidney cancer suggests potential biomarkers for treatment selection. Another study on tegavivint, targeting the Wnt/β-catenin pathway in liver cancer, shows promise with an objective response rate of 22%. These findings underscore the shift towards personalized, biology-driven cancer treatments. 
